Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western population

Abstract

Background and study aim Pre-endoscopic use of a preparation with tensioactive and mucolytic agents improved gastric mucosa visualization in Eastern studies. Data on Western population are scanty.

Patients and methods This prospective, endoscopist-blinded, randomized study enrolled patients who underwent esophagogastroduodenoscopy in a single center. Before endoscopy patients, were randomized to receive or not receive an oral preparation with simethicone and N-acetylcysteine in water. A pretested score (Crema Stomach Cleaning Score [CSCS]) for gastric mucosa cleaning evaluation was used. In detail, the stomach was divided into the antrum, body, and fundus and a score of 1 to 3 was assigned to each part (the higher the score, the better the preparation), and a total value ≤ 5 was considered as insufficient. Time between endoscope insertion and clean achievement (mouth to clean time) or the end of examination (mouth to mouth time) was recorded.

Results A total of 197 patients were enrolled. The mean overall CSCS value and mucosal cleaning in all parts was better in treated patients than in controls. Prevalence total score ≤ 5 was significantly lower in patients treated before endoscopy. Need for water flush occurred less frequently in treated patients (P < 0.0001). The mouth to clean time was lower in the treated than in the control group (2.3 ± 1.6 vs 3.8 ± 1.6 min; P < 0.001), whereas no significant difference in mouth to mouth time emerged.

Conclusions Data from this study show that premedication with simethicone and N-acetylcysteine results in significantly better endoscopic visualization of gastric mucosa, and the proposed CSCS could be useful for standardizing this evaluation.

• References

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018; 68: 394-424
• 2 Arnold M, Park JY, Camargo MC. et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035.. Gut 2020; 69: 823-829
• 3 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
• 4 Lai EJ, Calderwood AH, Doros G. et al. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc 2009; 69: 620-625
• 5 Beg S, Ragunath K, Wyman A. et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut 2017; 66: 1886-1899
• 6 Chang WK, Yeh MK, Hsu HC. et al. Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy: premedication before upper endoscopy. J Gastroenterol Hepatol 2014; 29: 769-774
• 7 Chang C-C, Chen S-H, Lin C-P. et al. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol 2007; 13: 444-447
• 8 Sajid MS, Rehman S, Chedgy F. et al. Improving the mucosal visualization at gastroscopy: a systematic review and meta-analysis of randomized, controlled trials reporting the role of Simethicone ± N-acetylcysteine. Transl Gastroenterol Hepatol 2018; 3: 29
• 9 Elvas L, Areia M, Brito D. et al. Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial. Endoscopy 2016; 49: 139-145
• 10 Basford PJ, Brown J, Gadeke L. et al. A randomized controlled trial of pre-procedure simethicone and N-acetylcysteine to improve mucosal visibility during gastroscopy – NICEVIS. Endosc Int Open 2016; 4: E1197-E202
• 11 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
• 12 Monrroy H, Vargas JI, Glasinovic E. et al. Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest End 2018; 87: 986-993
• 13 Zullo A, Manta R, De Francesco V. et al. Diagnostic yield of upper endoscopy according to appropriateness: a systematic review. Dig Liver Dis 2019; 51: 335-339
• 14 Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? Meta-analysis. . End Int Open 2014; 2: E46-E50
• 15 Yakamarthi S, Witherpoon P, McCole D. et al. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 2005; 36: 874-879
• 16 Marrelli D, Pedrazzani C, Morgagni P. et al. Changing clinical and pathological features of gastric cancer over time. Br J Surg 2011; 98: 1273-1283
• 17 Cha JM, Won KY. et al. Effect of pronase premedication on narrow-band imaging endoscopy in patients with precancerous conditions of stomach. Dig Dis Sci 2014; 59: 2735-2741
• 18 Li Y, Du F, Fu D. The effect of using simethicone with or without N-acetylcysteine before gastroscopy: a meta-analysis and systemic review. Saudi J Gastroenterol 2019; 25: 218-222
• 19 Park JM, Huo SM. et al. Longer observation time increases proportion of neoplasms detected by esophagogastroduodenoscopy. Gastroenterology 2017; 153: 460-469
• 20 Asl SMKH. Efficacy of premedication with activated Dimethicone or N-acetylcysteine in improving visibility during upper endoscopy. World J Gastroenterolog 2011; 17: 4213
• 21 Zullo A, Esposito G, Ridola L. et al. Prevalence of lesions detected at upper endoscopy: an Italian survey. Eur J Int Med 2014; 25: 772-776